Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge
Massachusetts
02139
United States
Tel: 617-679-5500
Fax: 617-679-5592
Website: http://www.iderapharma.com/
Email: info@iderapharma.com
About Idera Pharmaceuticals, Inc.
Idera Pharma develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.For more information, visit www.iderapharma.com.
368 articles about Idera Pharmaceuticals, Inc.
-
Idera Pharmaceuticals and BioCryst Pharmaceuticals originally planned on January 22, 2018 to merge the two companies. Now the two companies announced the deal has been terminated.
-
BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals
7/10/2018
BioCryst Pharmaceuticals, Inc. announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc. following the BioCryst stockholders’ failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders held today.
-
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
-
ASCO 2018: Results Keep Rolling In
6/4/2018
There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories. -
Idera Pharmaceuticals Increases Operational Efficiency of Global Oncology Program with Medidata Clinical Cloud
5/1/2018
Medidata’s Solutions to Accelerate Studies, Improve Data Quality, and Drive Greater Patient Enrollment
-
BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals
4/2/2018
BioCryst Mails Letter to Stockholders Highlighting Compelling Upside Opportunity
-
The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of Idera, who will also serve as a member of the Board.
-
Idera Pharmaceuticals Provides 2018 Update and Outlook
1/5/2018
Company to present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:00 AM PT/2:00 PM ET.
-
Why investors may want to keep an eye on Idera Pharmaceuticals and Ekso Bionics.
-
U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma
11/29/2017
FDA’s Fast Track program is designed to expedite the development and review of drugs and biologics to treat serious or life-threatening conditions.
-
Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)
11/9/2017
These data will be presented at 4:45 P.M. E.T. on Saturday, November 11th.
-
Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/7/2017
Net loss applicable to common stockholders for the three months ended September 30, 2017 was $14.5 million, or $0.10 per basic and diluted share, compared to a net loss applicable to common stockholders of $12.9 million.
-
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10/26/2017
The Company has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock
-
Idera Pharmaceuticals Provides Corporate Governance Update
10/25/2017
Youssef El Zein, Managing Partner of Pillar Invest Corporation has elected to step down from the company’s Board of Directors, effective immediately.
-
Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
10/25/2017
The company intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In connection with this offering.
-
Idera Pharma Presents Positive Phase I Data For Intratumoral IMO-2125 In Combination With Ipilimumab Demonstrating An Overall Response Rate (ORR) Of 44% In Melanoma Patients Refractory To Anti-PD1 Therapy
9/11/2017
-
Idera Pharma Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-Tumor Responses Associated With Tumor-Specific Memory
9/8/2017
-
Idera Pharma To Host Investor Conference Call On Monday, September 11, 2017 At 9:00 A.M. E.T.
9/7/2017
-
Idera Pharma Reports Second Quarter 2017 Financial Results And Provides Corporate Update
8/8/2017
-
Idera Pharma Reports First Quarter 2017 Financial Results And Provides Corporate Update
5/5/2017